BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 11522648)

  • 21. Inhibitory effect of full-length human endostatin on in vitro angiogenesis.
    Taddei L; Chiarugi P; Brogelli L; Cirri P; Magnelli L; Raugei G; Ziche M; Granger HJ; Chiarugi V; Ramponi G
    Biochem Biophys Res Commun; 1999 Sep; 263(2):340-5. PubMed ID: 10491294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis.
    Xu R; Yao ZY; Xin L; Zhang Q; Li TP; Gan RB
    Biochem Biophys Res Commun; 2001 Nov; 289(1):264-8. PubMed ID: 11708810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
    Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
    Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
    Hedberg KK; Stauff C; Høyer-Hansen G; Rønne E; Griffith OH
    Exp Cell Res; 2000 May; 257(1):67-81. PubMed ID: 10854055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
    Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
    Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
    J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
    J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
    O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
    Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
    Kim YM; Jang JW; Lee OH; Yeon J; Choi EY; Kim KW; Lee ST; Kwon YG
    Cancer Res; 2000 Oct; 60(19):5410-3. PubMed ID: 11034081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.